胆固醇通路基因变异与角质形成细胞胆固醇减少支持过度增殖性炎症性皮肤病存在最终可成药共同通路
研究假说角质形成细胞内胆固醇代谢异常在过度增殖性炎症性皮肤病中普遍重要。采用二维气相色谱-三维质谱发现多种单基因过度增殖性炎症性皮肤病及斑块状银屑病原代角质形成细胞平均胆固醇显著降低,胆固醇/他汀体外可挽救细胞过度增殖。银屑病GWAS命中富集于脂质代谢通路基因附近,罕见变异亦富集,提示遗传变异参与银屑病易感性。
要点
- 过度增殖性炎症性皮肤病角质形成细胞胆固醇降低是共同异常。
- 胆固醇/他汀体外可挽救角质形成细胞过度增殖。
- 银屑病脂质代谢通路基因常见与罕见变异均富集。
核心结论
- 过度增殖性炎症性皮肤病存在角质形成细胞胆固醇代谢异常的最终共同通路,局部用药可避免首过代谢。
- 脂质通路基因遗传变异与银屑病易感性相关,可能解释血清脂质异常与银屑病共病。
研究设计与样本
- 研究采用原代角质形成细胞,来源包括炎症性线状疣状表皮痣(n=14)、CHILD综合征(n=2)、斑块状银屑病(n=2)及对照。
- 采用二维气相色谱-三维质谱检测胆固醇,并行体外胆固醇/他汀干预及银屑病GWAS的SNPsea与负担分析。
主要发现
- 所有患者组原代角质形成细胞平均胆固醇较对照组显著降低。
- 体外胆固醇和他汀治疗可挽救细胞过度增殖。
- 银屑病GWAS命中显著富集于脂质代谢通路基因邻近区域,罕见变异在患者中显著富集。
临床怎么用
- 提示局部应用胆固醇/他汀可能成为过度增殖性炎症性皮肤病的治疗策略。
- 银屑病患者可关注脂质代谢通路基因变异及血清脂质异常共病。
局限性
- 银屑病原代角质形成细胞样本量仅n=2,需更大样本验证。
- 体外挽救实验不能完全代表体内疗效,需临床研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperproliferative inflammatory skin disease (HISD) is frequently seen in rare monogenic diseases of cholesterol metabolism and responds to topical cholesterol/statin. We hypothesized that aberrant cholesterol metabolism within keratinocytes could be important in HISD more generally, driven by either immunological or lipid pathway genetic variation. Whereas other epidermal lipids have been well-characterized in HISDs, cholesterol and its metabolites have not. In this study, using comprehensive 2-dimensional gas chromatography 3-dimensional mass spectrometry, we found that primary keratinocytes from diverse monogenic HISDs (inflammatory linear verrucous epidermal nevi, n = 14; CHILD [congenital hemidysplasia with ichthyosiform erythroderma and limb defects] syndrome, n = 2) and from plaque psoriasis (n = 2) demonstrate significantly reduced mean cholesterol across all patient groups compared with those across the controls. This striking abnormality appears causally implicated because treatment in vitro with cholesterol and statin rescued the cellular hyperproliferation. Using SNPsea and burden analysis of large international psoriasis cohorts, we went on to show that GWAS hits were significantly enriched in proximity to genes encoding lipid metabolic pathways and that rare variants in lipid metabolic pathway genes were significantly enriched in patients with psoriasis. These data identify a final common pathway of aberrant keratinocyte cholesterol metabolism in HISD, which should be drugged topically to avoid first-pass metabolism. In parallel, we implicate genetic variation in lipid pathway genes in psoriasis susceptibility, potentially explaining the comorbidity of abnormal serum lipid profile and psoriasis.
引用
- Riachi M, Bryant D, Ellis J, et al. Cholesterol Pathway Gene Variants and Reduced Keratinocyte Cholesterol Support a Final Common Druggable Pathway in Hyperproliferative Inflammatory Skin Diseases. J Invest Dermatol. 2025. PMID: 40274221. doi:10.1016/j.jid.2025.02.157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。